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tion carcinoma) 1 each from pulmonary metastasis and pleural ﬂuid. 
All showed several chromosomal abnormalities. With the modal 
number varying between 56 - 87 chromosomes. The consistent ﬁnding 
in 9/10 cases was a deletion of 3p while 1 had a translocation involving 
chromosome 3. 
In this study tumors irrespective of being a NSCLC or SCLC showed 
that chromosome 3 was consistently involve hinting that this cytoge-
netic proﬁle could evolve as a new diagnostic tool in difﬁcult clinical 
situations. 
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Background: Down-regulation or loss of human leukocyte antigen 
(HLA) class I has been reported in various malignancies in associa-
tion with poor patient survival. These ﬁndings may reﬂect an escape 
of tumor cells losing intact HLA class I molecules from HLA class 
I-restricted, tumor-associated antigen-speciﬁc cytotoxic T lymphocytes 
in recognition as well as in destruction. However, clinical impact of the 
down-regulation or loss of HLA class I in patients with non-small cell 
lung cancer (NSCLC) is still unknown. In the present study, we inves-
tigated clinical signiﬁcance of alteration in expression of HLA class I 
molecules in surgically resected NSCLC using tissue array analysis.
Method: Formalin-ﬁxed parafﬁn-embedded sections were obtained 
from 105 NSCLC (60 adenocarcinoma, 37 squamous cell carcinoma, 
and 6 large cell carcinoma). HLA class I and β2- microglobulin expres-
sion were analyzed using tissue array analysis. Imuunohistochemical 
study was performed using anti-HLA class I mAb EMR8-5 and anti-
β2- microglobulin mAb BBM1/sc-13565. Correlation between HLA 
class I or β2- microglobulin expression and clinicopathological param-
eter was analyzed statistically. Additionally, survival analysis was also 
performed using Kaplan-Meier’s method.
Result: There was no signiﬁcant correlation between HLA class I 
and clinicopathological parameters. On the other hand, signiﬁcant 
correlations were observed between β2- microglobulin expression 
and tumor size(p=0.0003), histological subtype(p=0.0285), nodal 
status(p=0.0335),and pathological stage(p=0.0335). Loss of β2- mi-
croglobulin expression was correlated with poor patient survival 
(p=0.0121), although HLA class I was not(p=0.8243).
Conclusion: Although clinical impact of HLA alteration was still 
unclear, β2- microglobulin expression might be involved in cancer 
progression in human NSCLC possibly through aberration of several 
molecules which contains β2- microglobulin.
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Purpose: To assess the activation patterns of RTK pathways, i.e. pro-
tein kinase B (PKB/Akt) and mitogen activated protein kinase (MAPK) 
pathways, in lung adenocarcinoma as compared with clinico-pathologi-
cal factors and status of EGFR and KRAS mutations. 
Experimental Design: 99 evaluable cases with primary lung adenocar-
cinomas surgically resected between 1998 and 1999 were selected for 
this study. Akt and MAPK phosphorylation (pAkt and pMAPK) was 
examined by means of immunohistochemistry. We deﬁned that cases 
with pAkt+/pMAPK- immunoreactivity to be the “Akt pathway type” 
and the pAkt-/pMAPK+ pattern to be the “MAPK pathway type.” Both 
positive and negative controls were prepared using mouse xenografts 
of PC-3 (pAkt+/MAPK-) and HTB26 (pAkt-/pMAPK+) cell lines. 
Univariate and multivariate analysis were performed to evaluate the 
association of these downstream mainly activated pathways and clinical 
signiﬁcance. The mutational status of EGFR and KRAS was deter-
mined by direct sequencing.
Results: Of the 99 cases, rates of the Akt pathway type and the MAPK 
pathway type were 32% (n=32) and 29% (n=29), respectively. Cases 
with immunoreactivity to both of the antibodies were not included 
in either type. Mutation assay revealed EGFR mutations in 55 cases 
(55%), and KRAS mutation in 7 cases (7%). The predictive factors for 
the MAPK pathway type were cumulative smoking and KRAS muta-
tion by univariate analysis. As all the cases with KRAS mutations were 
strongly positive for pMAPK, KRAS mutation status was mostly a 
highly predictive factor for the Akt pathway type.
Conclusions: Association between Ras/MAPK pathways activa-
tion and KRAS mutations was conﬁrmed in tumor specimens of lung 
adenocarcinoma. The MAPK pathway type was statistically associated 
also with cumulataive smoking. 
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Background: The incidence of lung adenocarcinoma in Korea is 
increasing recently. Estrogen and EGFR pathway may be important in 
lung cancer carcinogenesis. This study was conducted to investigate the 
relationship among expression rate of estrogen receptor(ER), ERCC1, 
Kras and EGFR mutation in adenocarcinoma of the lung.
Material and Method: We performed the retrospective review of 
clinical information that diagnosed as adenocarcinoma of lung at Kosin 
University Gospel Hospital, Busan, South Korea from January 1999 to 
September 2005. Patient’s demographics, stage, serum tumor markers, 
pathologic classiﬁcation were analyzed. EGFR mutations in exons: 18, 
19, 20, 21, and K-ras mutation in exon 12, 13 were analyzed by DNA 
sequencing. The prevalence of ERα, ERβ, and ERCC1 were assessed 
by standard immuonohistochemical (IHC) methods using formalin-
ﬁxed, parafﬁn-embeded tumor specimens. 
Results: For all 84 patients with adenocarcinoma (stage IA in 10, IB 
22, IIA 6, IIB 7, IIIA 25, IIIB 7, and IV 7), 43 (51.2%) were male, 41 
(48.8%) female, and mean age was 57 years old. Mutations of EGFR 
mutations and KRAS were present in 25.7%, 9.5% of samples, respec-
tively. In IHC stain, ER expression was 65.5%, ERα expression in 
41.7%, ERβ in 51.2%, and both expressions in 27.4%. The expression 
rate of ERCC1 was 31%. There were correlation between ER expres-
sion and ERCC1 expression especially in ERβ expression (p=0.000). 
However there was no correlation between ER expression and EFGR 
